Showing 861 - 880 results of 3,784 for search '"hypertension"', query time: 0.07s Refine Results
  1. 861
  2. 862
  3. 863
  4. 864
  5. 865
  6. 866

    Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis by Yusi Chen, Fang Li, Jun Luo, Jingyuan Chen, Peng Luo, Jiang Li

    Published 2021-01-01
    “…There is significant controversy relating to whether chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with pulmonary arterial hypertension- (PAH-) targeted therapies and which therapy is the optimal choice for patients. …”
    Get full text
    Article
  7. 867
  8. 868

    Spleen and Liver Stiffness Evaluation by ARFI Imaging: A Reliable Tool for a Short-Term Monitoring of Portal Hypertension? by Andreas Binzberger, Mark Hänle, Matthias Pfahler, Wolfgang Kratzer, Thomas Seufferlein, Eugen Zizer

    Published 2022-01-01
    “…Assessment of hepatic venous pressure gradient (HVPG) is the most reliable, though invasive method for evaluation of portal hypertension. Non-invasive, elastography-based techniques are well established in diagnosis, but not in monitoring of portal hypertension. …”
    Get full text
    Article
  9. 869
  10. 870
  11. 871

    Antioxidant Potential of Adiponectin and Full PPAR-γ Agonist in Correcting Streptozotocin-Induced Vascular Abnormality in Spontaneously Hypertensive Rats by Sheryar Afzal, Munavvar Abdul Sattar, Edward James Johns, Olorunfemi A. Eseyin, Ali Attiq

    Published 2021-01-01
    “…We investigated pharmacodynamically the pathophysiological role and potential implication of exogenously administered adiponectin with full and partial peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists on modulation of oxidative stress, metabolic dysregulation, and antioxidant potential in streptozotocin-induced spontaneously hypertensive rats (SHR). Group I (WKY) serves as the normotensive control, whereas 42 male SHRs were randomized equally into 7 groups (n=6); group II serves as the SHR control, group III serves as the SHR diabetic control, and groups IV, V, and VI are treated with irbesartan (30 mg/kg), pioglitazone (10 mg/kg), and adiponectin (2.5 μg/kg), whereas groups VII and VIII received cotreatments as irbesartan+adiponectin and pioglitazone+adiponectin, respectively. …”
    Get full text
    Article
  12. 872
  13. 873
  14. 874
  15. 875
  16. 876

    Early Pregnancy Serum Metabolite Profiles Associated with Hypertensive Disorders of Pregnancy in African American Women: A Pilot Study by Erin P. Ferranti, Jennifer K. Frediani, Rebecca Mitchell, Jolyn Fernandes, Shuzhao Li, Dean P. Jones, Elizabeth Corwin, Anne L. Dunlop

    Published 2020-01-01
    “…Hypertensive disorders of pregnancy (HDP) are the most common cardiometabolic complications of pregnancy, affecting nearly 10% of US pregnancies and contributing substantially to maternal and infant morbidity and mortality. …”
    Get full text
    Article
  17. 877
  18. 878
  19. 879
  20. 880

    Impact of urbanisation on the gaps of hypertension prevalence, awareness and treatment among older age in China: a cross-sectional study by Qiutong Yu, Genyong Zuo

    Published 2022-06-01
    “…Hypertension awareness was defined as a previous diagnosis of hypertension by a health professional, and hypertension treatment was defined as undergoing BP treatment.Results The prevalence of hypertension was lower among semiurbanised adults than among non-urbanised rural adults (OR=0.94, 95% CI=0.90 to 0.99; p<0.05). …”
    Get full text
    Article